FAQ on Clene Inc.'s Q1 2025 Results and CNM-Au8 Program Advancements

What is Clene Inc. focusing on with its CNM-Au8 program?

Clene Inc. is focusing on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS) with its CNM-Au8 program.

What significant progress did Clene report for CNM-Au8 in ALS treatment?

Clene reported that CNM-Au8 significantly improved survival in patients with more severe ALS and is preparing for a potential NDA submission under the FDA’s Accelerated Approval pathway for ALS in Q4 2025.

How did CNM-Au8 perform in MS treatment according to the latest data?

In MS, Clene presented Phase 2 extension results demonstrating that CNM-Au8 contributed to remyelination and neuronal repair.

What were Clene’s financial results for Q1 2025?

Clene reported a Q1 net loss of $0.8 million on reduced expenses and had $9.8 million in cash, funding operations into Q3 2025.

Where can I find more information about Clene Inc. and its programs?

For more information, please visit www.Clene.com or the company’s newsroom at https://ibn.fm/CLNN.

What is the significance of the FDA’s Accelerated Approval pathway for Clene’s CNM-Au8?

The FDA’s Accelerated Approval pathway could allow for earlier approval of CNM-Au8 for ALS based on survival data and upcoming biomarker analysis, potentially speeding up access to this treatment for patients.

Where is Clene Inc. based?

Clene Inc. is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland.

What is CNM-Au8’s mechanism of action?

CNM-Au8 improves central nervous system cells’ survival and function via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress.